Press Releases

DAY HI:
DAY LOW:
VOLUME:

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Mar 07, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 7, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy
Mar 06, 2018
Poziotinib: following promising interim results, the Company is actively enrolling NSCLC patients with exon 20 insertion mutation in a multi-center study. ROLONTIS ™ (eflapegrastim): ADVANCE study recently met the primary efficacy endpoint; RECOVER study fully enrolled; BLA filing expected in Q4
Feb 27, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 27, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced the appointment of William L.
Feb 26, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 26, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with
Feb 15, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 15, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business
Feb 05, 2018
The ADVANCE study met the primary efficacy endpoint of non-inferiority in Duration of Severe Neutropenia between ROLONTIS and pegfilgrastim; adverse event profile was similar between the two treatment arms. RECOVER, the second Phase 3 study, is now fully enrolled.
Jan 23, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 23, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business
Dec 17, 2017
Joseph W. Turgeon Named President and CEO and Elected to the Board of Directors Thomas J. Riga Named Chief Operating Officer Stuart M. Krassner , ScD, PsyD Named Chairman of the Board HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), a biotechnology company with
Dec 13, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced two oral presentations of data on FOLOTYN and research progress for the
Dec 04, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its
Nov 08, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals , Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and
Nov 02, 2017
Poziotinib: Objective Response Rate of 73% was observed in preliminary analysis from an ongoing Phase 2 study conducted by MD Anderson Cancer Center in Non-Small-Cell Lung Cancer (NSCLC) patients with EGFR exon 20 insertion mutations. The Company has initiated a multicenter clinical trial to
Oct 30, 2017
The study will evaluate Objective Response Rate (ORR) as the primary endpoint. Objective Response Rate of 73% was observed in preliminary analysis of an ongoing Phase 2 study being conducted by Dr. John Heymach at the University of Texas MD Anderson Cancer Center .
Oct 26, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with management to
Oct 17, 2017
Poziotinib demonstrates evidence of significant antitumor activity in NSCLC patients with EGFR exon 20 insertion mutations, with interim data showing an Objective Response Rate of 73%. Evidence of central nervous system (CNS) activity in a patient with CNS metastasis and another with leptomeningeal
Oct 10, 2017
Approximately $40.5 Million in Principal Amount of Notes Will Be Outstanding Following the Exchanges HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) today announced that it has entered into separate, privately negotiated exchange agreements with certain holders
Sep 29, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced that between August 11, 2017 and September 29, 2017 , it issued an
Sep 28, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced the release of an abstract from a clinical study evaluating
Sep 05, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and
Aug 17, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and
Displaying 61 - 80 of 791